Pathstone Family Office’s Strata Critical Medical Inc SRTA Stock Holding History

Pathstone Family Office’s Portfolio SRTA Stock Details SRTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$36.3K	Buy	+14,032	New	+$49.3K	﹤0.01%	1636

Other funds holding SRTA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NRCM

Northern Right Capital Management Darien, Connecticut $337M AUM 63.03% 1-Year Est. Return

UIC

Uniplan Investment Counsel Milwaukee, Wisconsin $1.07B AUM 34.04% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pathstone Family Office's SRTA Position: Q3 2023 in Review

Pathstone Family Office opened a new position in Strata Critical Medical Inc (SRTA) in Q3 2023: 14,032 shares worth $36.3K. The stake represents ﹤0.01% of the portfolio and ranks #1636 among its holdings.

105 funds tracked by Wall St. Rank hold SRTA as of Q3 2023.

Pathstone Family Office held 14,032 shares of Strata Critical Medical Inc worth $36.3K as of Q3 2023.
Strata Critical Medical Inc was a new Pathstone Family Office position in Q3 2023.
Strata Critical Medical Inc made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1636 holding.
105 funds tracked by Wall St. Rank held Strata Critical Medical Inc as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.